Lv4
530 积分 2026-03-26 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
8天前
已完结
Small animal DXA instrument comparison and validation
10天前
已完结
Targeting USP8 with odoroside A regulates LXRβ-mediated fatty acid metabolic reprogramming against colorectal cancer
11天前
已完结
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo
14天前
已完结
Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study
17天前
已完结
Pancreatic metastases are suppressed by photodynamic therapy and irinotecan through macrophage reprogramming in immunodeficient mice
1个月前
已完结
SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma
1个月前
已完结
Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug
1个月前
已完结
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas
1个月前
已完结
Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2)
1个月前
已完结
皖公网安备34019202002308
